CL2018003132A1 - Inhibidores de la arginasa y sus aplicaciones terapéuticas. - Google Patents

Inhibidores de la arginasa y sus aplicaciones terapéuticas.

Info

Publication number
CL2018003132A1
CL2018003132A1 CL2018003132A CL2018003132A CL2018003132A1 CL 2018003132 A1 CL2018003132 A1 CL 2018003132A1 CL 2018003132 A CL2018003132 A CL 2018003132A CL 2018003132 A CL2018003132 A CL 2018003132A CL 2018003132 A1 CL2018003132 A1 CL 2018003132A1
Authority
CL
Chile
Prior art keywords
arginase
therapeutic applications
arginase inhibitors
convention
inhibitors
Prior art date
Application number
CL2018003132A
Other languages
English (en)
Inventor
Roman Blaszczyk
Julita Nowicka
Bartlomiej Borek
Joanna Brzezinska
Anna Gzik
Marek Dziegielewski
Adam Golebiowski
Karol Jedrzejczak
Krzysztof Matyszewski
Jacek Olczak
Original Assignee
Oncoarendi Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoarendi Therapeutics Sa filed Critical Oncoarendi Therapeutics Sa
Publication of CL2018003132A1 publication Critical patent/CL2018003132A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE DESCRIBEN COMPUESTOS TERAPÉUTICOS DE MOLÉCULAS PEQUEÑAS QUE SON POTENTES INHIBIDORES DE LA ACTIVIDAD DE LA ARGINASA 1 Y ARGINASA 2. TAMBIÉN SE DESCRIBEN COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS COMPUESTOS Y MÉTODOS PARA USAR LOS COMPUESTOS PARA TRATAR O PREVENIR UNA ENFERMEDAD O AFECCIÓN ASOCIADA CON LA ACTIVIDAD DE LA ARGINASA.
CL2018003132A 2016-05-04 2018-11-05 Inhibidores de la arginasa y sus aplicaciones terapéuticas. CL2018003132A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662331550P 2016-05-04 2016-05-04
PL417066A PL417066A1 (pl) 2016-05-04 2016-05-04 Inhibitory arginazy oraz ich zastosowania terapeutyczne
US201762444669P 2017-01-10 2017-01-10

Publications (1)

Publication Number Publication Date
CL2018003132A1 true CL2018003132A1 (es) 2019-02-22

Family

ID=60190450

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003132A CL2018003132A1 (es) 2016-05-04 2018-11-05 Inhibidores de la arginasa y sus aplicaciones terapéuticas.

Country Status (24)

Country Link
US (3) US10391077B2 (es)
EP (1) EP3452485B1 (es)
JP (1) JP6971477B2 (es)
KR (1) KR102374788B1 (es)
CN (1) CN109415387B (es)
AU (1) AU2017259887B2 (es)
BR (1) BR112018072545B1 (es)
CA (1) CA3022482C (es)
CL (1) CL2018003132A1 (es)
CO (1) CO2018013077A2 (es)
DK (1) DK3452485T3 (es)
ES (1) ES2834065T3 (es)
HR (1) HRP20201821T1 (es)
HU (1) HUE052468T2 (es)
IL (1) IL262387B (es)
LT (1) LT3452485T (es)
MX (1) MX2018013387A (es)
PE (1) PE20181924A1 (es)
PH (1) PH12018501976A1 (es)
PL (2) PL417066A1 (es)
SA (1) SA518400356B1 (es)
SG (1) SG11201807974QA (es)
SI (1) SI3452485T1 (es)
WO (1) WO2017191130A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2632927T1 (sl) 2010-10-26 2016-08-31 Mars, Incorporated Boronati kot inhibitorji arginaze
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
LT3368541T (lt) 2015-10-30 2020-09-25 Calithera Biosciences, Inc. Kompozicijos ir būdai, skirti arginazės aktyvumo inhibavimui
TW201735792A (zh) 2016-03-07 2017-10-16 農業保鮮股份有限公司 使用苯并氧雜硼雜環戊烯化合物和防腐氣體作為作物的抗微生物劑之協同方法
PL417066A1 (pl) * 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
SI3559009T1 (sl) 2016-12-22 2021-08-31 Calithera Biosciences, Inc. Sestavki in postopki za zaviranje arginazne dejavnosti
CN117180290A (zh) 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
IL276813B2 (en) 2018-03-05 2024-09-01 Arcus Biosciences Inc History of 4-substituted 5-amino-octahydrocyclopenta[c]pyrrole-5-carboxylic acid, their pharmaceutical combinations and their use for the treatment of diseases
US20210040127A1 (en) * 2018-03-13 2021-02-11 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
TWI723366B (zh) * 2018-03-29 2021-04-01 波蘭商昂科艾倫迪治療法股份公司 二肽哌啶衍生物
EP3810615A4 (en) * 2018-06-20 2022-03-30 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
US20220056051A1 (en) * 2018-12-18 2022-02-24 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
EP4087583A4 (en) * 2020-01-07 2024-01-24 Merck Sharp & Dohme LLC ARGINASE INHIBITORS AND METHODS OF USE
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
WO2024209358A1 (en) 2023-04-06 2024-10-10 Molecure S.A. Process for the production of (1r,2s,5r)-1-amino-5-[2-(dihydroxyboranyl)ethyl]-2-[(dimethylamino)methyl]cyclohexane-1-carboxylic acid

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
WO1999019295A1 (en) 1997-10-10 1999-04-22 Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting arginase activity
EP1604977A1 (en) 2004-06-02 2005-12-14 Faust Pharmaceuticals CIS pyrrolidinyl derivatives and their uses
EP1604978A1 (en) 2004-06-02 2005-12-14 Faust Pharmaceuticals Trans pyrrolidinyl derivatives and their pharmaceutical uses
US20100056480A1 (en) 2006-11-21 2010-03-04 Rijks Univesiteit Groningen Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
RS58965B1 (sr) 2009-01-26 2019-08-30 Univ Pennsylvania Inhibitori arginaze i postupci upotrebe
MX348422B (es) 2010-04-22 2017-06-12 Mars Inc Inhibidores de arginasa y sus aplicaciones terapeuticas.
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
SI2632927T1 (sl) 2010-10-26 2016-08-31 Mars, Incorporated Boronati kot inhibitorji arginaze
US8894970B2 (en) 2010-12-31 2014-11-25 Corridor Pharmaceuticals, Inc. Arginase inhibitors and methods of use thereof
JP5993459B2 (ja) 2011-10-19 2016-09-14 マーズ インコーポレイテッド アルギナーゼ阻害剤およびそれらの治療用途
IN2014DN09678A (es) * 2012-04-18 2015-07-31 Mars Inc
LT2872515T (lt) 2012-07-13 2016-10-10 Janssen Sciences Ireland Uc Makrocikliniai purinai, skirti virusinių infekcijų gydymui
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
EP3313410A4 (en) 2015-06-23 2019-01-02 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
LT3368541T (lt) 2015-10-30 2020-09-25 Calithera Biosciences, Inc. Kompozicijos ir būdai, skirti arginazės aktyvumo inhibavimui
PL417066A1 (pl) * 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
US11291674B2 (en) 2016-11-08 2022-04-05 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
JP2021517454A (ja) 2018-01-28 2021-07-26 ユニベルシテ ドゥ ジュネーブ 癌治療のためのアルギナーゼ抑制

Also Published As

Publication number Publication date
IL262387B (en) 2021-10-31
CN109415387A (zh) 2019-03-01
HUE052468T2 (hu) 2021-04-28
EP3452485A2 (en) 2019-03-13
WO2017191130A3 (en) 2017-12-14
SI3452485T1 (sl) 2021-01-29
US10912755B2 (en) 2021-02-09
MX2018013387A (es) 2019-02-28
US20210260019A1 (en) 2021-08-26
IL262387A (en) 2018-12-31
KR102374788B1 (ko) 2022-03-15
SA518400356B1 (ar) 2022-01-19
BR112018072545B1 (pt) 2022-08-23
JP6971477B2 (ja) 2021-11-24
BR112018072545A2 (pt) 2019-06-25
CN109415387B (zh) 2021-08-27
US20190365701A1 (en) 2019-12-05
PL3452485T3 (pl) 2021-04-19
LT3452485T (lt) 2020-12-28
PH12018501976A1 (en) 2019-07-01
JP2019518726A (ja) 2019-07-04
DK3452485T3 (da) 2020-11-09
CO2018013077A2 (es) 2019-04-30
WO2017191130A4 (en) 2018-03-01
HRP20201821T1 (hr) 2021-04-16
SG11201807974QA (en) 2018-10-30
US10391077B2 (en) 2019-08-27
AU2017259887B2 (en) 2022-03-17
WO2017191130A2 (en) 2017-11-09
EP3452485B1 (en) 2020-09-09
US20170319536A1 (en) 2017-11-09
PE20181924A1 (es) 2018-12-11
CA3022482A1 (en) 2017-11-09
KR20190015250A (ko) 2019-02-13
ES2834065T3 (es) 2021-06-16
US12053451B2 (en) 2024-08-06
PL417066A1 (pl) 2017-11-06
AU2017259887A1 (en) 2018-09-27
CA3022482C (en) 2024-06-11

Similar Documents

Publication Publication Date Title
CL2018003132A1 (es) Inhibidores de la arginasa y sus aplicaciones terapéuticas.
CL2019000820A1 (es) Compuestos, composiciones y sus usos para inhibir la actividad arginasa. (divisional solicitud 201801134)
CO2019007839A2 (es) Composiciones y métodos para inhibir la acción de la arginasa
CL2021001179A1 (es) Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596).
EA202091186A1 (ru) ИНГИБИТОРЫ KRas G12C
CL2018002928A1 (es) Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2.
CO2017011183A2 (es) Inhibidores de indolamina-2,3-dioxigenasa composiciones que los contienen y métodos de preparación
MX2020003857A (es) Anticuerpos anti-tau y uso de los mismos.
CR20190271A (es) Anticuerpos antitau y métodos de uso
BR112019012343A2 (pt) anticorpos il-11ra
CL2018000687A1 (es) Nuevos compuestos bicíclicos como inhibidores de atx.
BR112019012342A2 (pt) anticorpos il-11
CO2017002532A2 (es) Indazoles sustituidos con bencilo como inhibidores de bub1
CO2019002239A2 (es) Formulaciones, kits y métodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados
CL2016003261A1 (es) Formulación que comprende un profármaco de gemcitabina
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
CY1120095T1 (el) Αναστολεις της erk και μεθοδοι χρησης
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
CL2020002624A1 (es) Formulaciones de inmunoconjugado anti-cd79b estables.
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
CY1122287T1 (el) Ενωσεις χρησιμες για την αναστολη toy ror-γαμμα-τ
AR109376A1 (es) FORMULACIONES DE g-HIDROXIBUTIRATO DE LIBERACIÓN MODIFICADA
CY1121105T1 (el) Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
UY37432A (es) Moléculas que tienen actividad pesticida, compuestos intermedios, composiciones y procesos relacionados